![]() ![]() In acquiring Eximo and its laser technology, AngioDynamics enters a growing $500+ million market with an innovative medical solution that offers greater versatility, a wider range of treatments, and strong clinical data to support its efficacy.ĭifferentiated from other legacy medical devices, Eximo’s laser technology is the only system capable of delivering short, high-powered pulsed-laser energy in 355nm wavelength without compromising the integrity of its fiber optic cables during atherectomy procedures. Physicians provide atherectomy treatment to over 200,000 Americans annually 1, and Eximo’s laser technology represents a technological breakthrough among medical devices used in atherectomy procedures to treat PAD today. “The market is ripe for disruption, and the level of precision, safety, and efficiency offered to physicians by this laser technology creates a substantially differentiated alternative to legacy atherectomy devices.” “The acquisition of Eximo brings a remarkable, foundational technology to our portfolio that will change the way caregivers deliver treatment to patients with PAD,” said Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. The Eximo technology complements AngioDynamics’ leading thrombus management and venous insufficiency technologies. This transaction expands AngioDynamics’ existing Vascular Interventions and Therapies (VIT) product portfolio by adding Eximo’s proprietary laser technology, which has received 510(k) clearance for use in the treatment of Peripheral Artery Disease (PAD). The transaction is being funded exclusively through the use of cash on hand. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has acquired Eximo Medical, Ltd., an early commercial stage, medical device company, and its proprietary 355nm wavelength laser-technology platform for $46 million in up-front consideration with up to $20 million of contingent consideration related to certain technical and revenue milestones. The data presented on this page does not represent the view of Eximo and its employees or that of Zippia.Įximo may also be known as or be related to EXIMO, LLC, Eximo and Eximo Inc.LATHAM, N.Y.-(BUSINESS WIRE)-Oct. None of the information on this page has been provided or approved by Eximo. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. ![]() ![]() Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. ![]() The employee data is based on information from people who have self-reported their past or current employments at Eximo. Zippia gives an in-depth look into the details of Eximo, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Eximo. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |